Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04249037 · ClinicalTrials.gov registry record · Phase 4
Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV
A Phase 4 study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT04249037 is a Phase 4 study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 10 participants.
The verdict
NCT04249037, a Phase 4 study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study plans to learn about whether starting HIV treatment very soon after diagnosis is more beneficial than waiting until entering routine clinical care after diagnosis.
Interventions
- DRUG bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF)
- DRUG Standard initiation of antiretroviral therapy (ART)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2023-07-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04249037
The ClinicalTrials.gov registry entry for NCT04249037 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) is the first listed.
NCT04249037 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04249037 about?
NCT04249037 is a clinical study titled "Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV". This study plans to learn about whether starting HIV treatment very soon after diagnosis is more beneficial than waiting until entering routine clinical care after diagnosis.
What is the current status of trial NCT04249037?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2020-12-15. Estimated completion is 2023-07-01.
What interventions are being tested in trial NCT04249037?
The interventions under investigation include: bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) (DRUG), Standard initiation of antiretroviral therapy (ART) (DRUG).
Who is sponsoring clinical trial NCT04249037?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.